| HOME >> BIOLOGY >> TECHNOLOGY |
(In Thousands, Except Share Data)
(Unaudited)
June 28, December 31,
2008 2007
ASSETS
Current assets:
Cash and cash equivalents $177,656 $200,132
Available for sale debt and marketable
equity securities 115,306 85,375
Accounts receivable, net 61,284 64,182
Inventories 51,774 84,887
Prepaid expenses and other current assets 15,684 14,294
Deferred income tax assets 54,868 56,921
Income taxes receivable 21,715 17,516
Total current assets 498,287 523,307
Property, plant and equipment, at cost less
accumulated depreciation and amortization 84,771 82,650
Available for sale debt and marketable
equity securities 5,156 6,690
Investment in joint venture - 6,314
Other investments 2,500 2,500
Intangible assets, net 55,350 36,059
Goodwill 63,729 63,729
Deferred financing costs and other assets 2,085 2,544
Non-current deferred income tax assets, net 59,252 57,730
Total assets $771,130 $781,523
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $200,000 $200,000
Accounts payable
'/>"/>
| SOURCE Par Pharmaceutical Companies, Inc. Copyright©2008 PR Newswire. All rights reserved |